Clinical Trial Update: Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial update on the tolerability of quinagolide given in a dose-titration regimen for oocyte donors at risk of ovarian hyperstimulation syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Hyperstimulation Syndrome

Drugs mentioned

• quinagolide (quinagolide)

Snippet

Sponsor: Instituto Valenciano de Infertilidad, IVI VALENCIA | Conditions: Ovarian Hyperstimulation Syndrome | Phase 2 | Status: COMPLETED